Fulcrum Therapeutics discontinues pociredir program, begins strategic review Jun 1, 2026 04:10PM
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review Jun 1, 2026 04:05PM
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025 Oct 29, 2025 07:00AM
Fulcrum Therapeutics reports Q2 results, pociredir trial data Jul 29, 2025 06:48AM
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 Jul 29, 2025 06:48AM


Jul 29, 2025 06:45AM Fulcrum reports positive Phase 1b trial results for sickle cell drug
Jul 29, 2025 06:45AM Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
May 1, 2025 07:00AM Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
Feb 25, 2025 07:00AM Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024
Nov 13, 2024 07:00AM Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
Sep 24, 2024 04:09PM Fulcrum Therapeutics Inc. (FULC) will reduce its workforce
Aug 11, 2022 07:00AM Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
Aug 11, 2022 07:00AM Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update